JP2008523083A - 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 - Google Patents

Info

Publication number

JP2008523083A

JP2008523083A JP2007545628A JP2007545628A JP2008523083A JP 2008523083 A JP2008523083 A JP 2008523083A JP 2007545628 A JP2007545628 A JP 2007545628A JP 2007545628 A JP2007545628 A JP 2007545628A JP 2008523083 A JP2008523083 A JP 2008523083A

Authority

JP

Japan

Prior art keywords

antagonist

multispecific

antibody

targets

inflammatory

Prior art date

2004-12-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 125
• 201000011510 cancer Diseases 0.000 title claims abstract description 99
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 84
• 238000000034 method Methods 0.000 title claims abstract description 83
• 201000010099 disease Diseases 0.000 title claims abstract description 49
• 208000034038 Pathologic Neovascularization Diseases 0.000 title claims abstract description 36
• 208000035473 Communicable disease Diseases 0.000 title claims abstract description 31
• 230000002757 inflammatory effect Effects 0.000 title claims abstract description 30
• 238000001514 detection method Methods 0.000 title claims description 47
• 239000000203 mixture Substances 0.000 title abstract description 34
• 238000009169 immunotherapy Methods 0.000 title abstract description 11
• 239000005557 antagonist Substances 0.000 claims abstract description 295
• 239000000427 antigen Substances 0.000 claims abstract description 108
• 108091007433 antigens Proteins 0.000 claims abstract description 108
• 102000036639 antigens Human genes 0.000 claims abstract description 108
• 210000004027 cell Anatomy 0.000 claims abstract description 93
• 230000000770 proinflammatory effect Effects 0.000 claims abstract description 86
• 239000012636 effector Substances 0.000 claims abstract description 84
• 238000011282 treatment Methods 0.000 claims abstract description 71
• 206010040047 Sepsis Diseases 0.000 claims abstract description 62
• 102000004127 Cytokines Human genes 0.000 claims abstract description 54
• 108090000695 Cytokines Proteins 0.000 claims abstract description 54
• 102000015081 Blood Coagulation Factors Human genes 0.000 claims abstract description 48
• 108010039209 Blood Coagulation Factors Proteins 0.000 claims abstract description 48
• 239000003114 blood coagulation factor Substances 0.000 claims abstract description 48
• 210000005007 innate immune system Anatomy 0.000 claims abstract description 43
• 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 37
• 208000035475 disorder Diseases 0.000 claims abstract description 35
• 210000002540 macrophage Anatomy 0.000 claims abstract description 35
• 206010040070 Septic Shock Diseases 0.000 claims abstract description 34
• 230000036303 septic shock Effects 0.000 claims abstract description 33
• 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 30
• 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 29
• 230000008938 immune dysregulation Effects 0.000 claims abstract description 29
• 208000015181 infectious disease Diseases 0.000 claims abstract description 29
• 206010006895 Cachexia Diseases 0.000 claims abstract description 17
• 230000015271 coagulation Effects 0.000 claims abstract description 17
• 238000005345 coagulation Methods 0.000 claims abstract description 17
• 210000004443 dendritic cell Anatomy 0.000 claims abstract description 17
• 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 15
• 210000001616 monocyte Anatomy 0.000 claims abstract description 14
• 208000009329 Graft vs Host Disease Diseases 0.000 claims abstract description 13
• 206010052779 Transplant rejections Diseases 0.000 claims abstract description 13
• 208000024908 graft versus host disease Diseases 0.000 claims abstract description 13
• 208000027866 inflammatory disease Diseases 0.000 claims abstract description 13
• 208000006673 asthma Diseases 0.000 claims abstract description 12
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract description 11
• 208000007465 Giant cell arteritis Diseases 0.000 claims abstract description 11
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract description 11
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims abstract description 11
• 206010043207 temporal arteritis Diseases 0.000 claims abstract description 11
• 206010018691 Granuloma Diseases 0.000 claims abstract description 10
• 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 9
• 208000015294 blood coagulation disease Diseases 0.000 claims abstract description 3
• 239000003814 drug Substances 0.000 claims description 90
• 230000000295 complement effect Effects 0.000 claims description 87
• 229940124597 therapeutic agent Drugs 0.000 claims description 69
• 102000005962 receptors Human genes 0.000 claims description 67
• 108020003175 receptors Proteins 0.000 claims description 67
• 239000000126 substance Substances 0.000 claims description 51
• 239000012634 fragment Substances 0.000 claims description 33
• 102000034356 gene-regulatory proteins Human genes 0.000 claims description 32
• 108091006104 gene-regulatory proteins Proteins 0.000 claims description 32
• 108020001507 fusion proteins Proteins 0.000 claims description 26
• 102000037865 fusion proteins Human genes 0.000 claims description 26
• -1 antibody Substances 0.000 claims description 21
• 239000003795 chemical substances by application Substances 0.000 claims description 20
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 18
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 18
• 102000004190 Enzymes Human genes 0.000 claims description 17
• 108090000790 Enzymes Proteins 0.000 claims description 17
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 17
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 17
• 239000002872 contrast media Substances 0.000 claims description 17
• 230000010121 inflammatory dysregulation Effects 0.000 claims description 17
• 108091034117 Oligonucleotide Proteins 0.000 claims description 16
• 210000005006 adaptive immune system Anatomy 0.000 claims description 14
• 229940127121 immunoconjugate Drugs 0.000 claims description 13
• 210000004180 plasmocyte Anatomy 0.000 claims description 13
• 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 12
• 101150013553 CD40 gene Proteins 0.000 claims description 12
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 12
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 12
• 239000004480 active ingredient Substances 0.000 claims description 12
• 238000003745 diagnosis Methods 0.000 claims description 12
• 239000002955 immunomodulating agent Substances 0.000 claims description 12
• 229940121354 immunomodulator Drugs 0.000 claims description 12
• 238000004519 manufacturing process Methods 0.000 claims description 12
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 10
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 10
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 10
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 10
• 239000002254 cytotoxic agent Substances 0.000 claims description 10
• 229940127089 cytotoxic agent Drugs 0.000 claims description 10
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 9
• 102000019034 Chemokines Human genes 0.000 claims description 9
• 108010012236 Chemokines Proteins 0.000 claims description 9
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 9
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 9
• 239000003667 hormone antagonist Substances 0.000 claims description 9
• 208000002874 Acne Vulgaris Diseases 0.000 claims description 8
• 102100032768 Complement receptor type 2 Human genes 0.000 claims description 8
• 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims description 8
• 206010000496 acne Diseases 0.000 claims description 8
• 239000004037 angiogenesis inhibitor Substances 0.000 claims description 8
• 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 8
• 239000002532 enzyme inhibitor Substances 0.000 claims description 8
• 230000002584 immunomodulator Effects 0.000 claims description 8
• 230000007823 neuropathy Effects 0.000 claims description 8
• 201000001119 neuropathy Diseases 0.000 claims description 8
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 8
• 206010053567 Coagulopathies Diseases 0.000 claims description 7
• 210000003714 granulocyte Anatomy 0.000 claims description 7
• 229940088597 hormone Drugs 0.000 claims description 7
• 239000005556 hormone Substances 0.000 claims description 7
• 230000033115 angiogenesis Effects 0.000 claims description 6
• 230000023555 blood coagulation Effects 0.000 claims description 6
• 210000002889 endothelial cell Anatomy 0.000 claims description 6
• 210000000822 natural killer cell Anatomy 0.000 claims description 6
• 210000001772 blood platelet Anatomy 0.000 claims description 5
• 230000004927 fusion Effects 0.000 claims description 5
• 230000004957 immunoregulator effect Effects 0.000 claims description 5
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 4
• 229910052796 boron Inorganic materials 0.000 claims description 4
• 229940125532 enzyme inhibitor Drugs 0.000 claims description 4
• 208000007536 Thrombosis Diseases 0.000 claims description 3
• 230000008021 deposition Effects 0.000 claims description 3
• VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 3
• 230000000392 somatic effect Effects 0.000 claims 2
• 208000011117 substance-related disease Diseases 0.000 claims 1
• 210000000987 immune system Anatomy 0.000 abstract description 26
• 206010061218 Inflammation Diseases 0.000 abstract description 17
• 230000004054 inflammatory process Effects 0.000 abstract description 17
• 210000000440 neutrophil Anatomy 0.000 abstract description 13
• 230000001154 acute effect Effects 0.000 abstract description 6
• 230000002519 immonomodulatory effect Effects 0.000 abstract description 3
• 208000037976 chronic inflammation Diseases 0.000 abstract description 2
• 208000037893 chronic inflammatory disorder Diseases 0.000 abstract description 2
• 210000005036 nerve Anatomy 0.000 abstract 1
• 108090000623 proteins and genes Proteins 0.000 description 55
• 241000282414 Homo sapiens Species 0.000 description 43
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 37
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 37
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 34
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 34
• 230000001225 therapeutic effect Effects 0.000 description 34
• 102000002262 Thromboplastin Human genes 0.000 description 33
• 108010000499 Thromboplastin Proteins 0.000 description 33
• 102000004169 proteins and genes Human genes 0.000 description 32
• 239000002158 endotoxin Substances 0.000 description 29
• 235000018102 proteins Nutrition 0.000 description 28
• 108090001005 Interleukin-6 Proteins 0.000 description 24
• 102000004889 Interleukin-6 Human genes 0.000 description 24
• 229940100601 interleukin-6 Drugs 0.000 description 24
• 229920006008 lipopolysaccharide Polymers 0.000 description 21
• 230000004044 response Effects 0.000 description 21
• 108090000765 processed proteins & peptides Proteins 0.000 description 20
• 230000008685 targeting Effects 0.000 description 20
• 102100031506 Complement C5 Human genes 0.000 description 19
• 108020004414 DNA Proteins 0.000 description 19
• 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 19
• 229940027941 immunoglobulin g Drugs 0.000 description 19
• 102000000589 Interleukin-1 Human genes 0.000 description 17
• 108010002352 Interleukin-1 Proteins 0.000 description 17
• 229940079593 drug Drugs 0.000 description 17
• 210000001519 tissue Anatomy 0.000 description 17
• 102000055207 HMGB1 Human genes 0.000 description 16
• 108700010013 HMGB1 Proteins 0.000 description 16
• 230000014509 gene expression Effects 0.000 description 16
• 239000010949 copper Substances 0.000 description 15
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
• 229940088598 enzyme Drugs 0.000 description 14
• 102000004196 processed proteins & peptides Human genes 0.000 description 14
• 244000005700 microbiome Species 0.000 description 13
• 230000037361 pathway Effects 0.000 description 13
• 230000002829 reductive effect Effects 0.000 description 13
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 12
• 241000699666 Mus <mouse, genus> Species 0.000 description 12
• 101800004937 Protein C Proteins 0.000 description 12
• 102000017975 Protein C Human genes 0.000 description 12
• 101800001700 Saposin-D Proteins 0.000 description 12
• 108090000190 Thrombin Proteins 0.000 description 12
• 230000028993 immune response Effects 0.000 description 12
• 229960000856 protein c Drugs 0.000 description 12
• 229960004072 thrombin Drugs 0.000 description 12
• 102100025680 Complement decay-accelerating factor Human genes 0.000 description 11
• 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 11
• 102000014150 Interferons Human genes 0.000 description 11
• 108010050904 Interferons Proteins 0.000 description 11
• 241000700605 Viruses Species 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 230000036039 immunity Effects 0.000 description 11
• 230000001976 improved effect Effects 0.000 description 11
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 11
• 238000002560 therapeutic procedure Methods 0.000 description 11
• 102000053602 DNA Human genes 0.000 description 10
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
• 108090001007 Interleukin-8 Proteins 0.000 description 10
• 102000004890 Interleukin-8 Human genes 0.000 description 10
• 102100039373 Membrane cofactor protein Human genes 0.000 description 10
• 238000013459 approach Methods 0.000 description 10
• 210000004369 blood Anatomy 0.000 description 10
• 239000008280 blood Substances 0.000 description 10
• 238000006243 chemical reaction Methods 0.000 description 10
• 230000000694 effects Effects 0.000 description 10
• 229940096397 interleukin-8 Drugs 0.000 description 10
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 10
• 229910052751 metal Inorganic materials 0.000 description 10
• 239000002184 metal Substances 0.000 description 10
• 230000001105 regulatory effect Effects 0.000 description 10
• 102100022002 CD59 glycoprotein Human genes 0.000 description 9
• 102100035793 CD83 antigen Human genes 0.000 description 9
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 9
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 9
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 9
• 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 9
• 230000024203 complement activation Effects 0.000 description 9
• 238000002591 computed tomography Methods 0.000 description 9
• 238000001802 infusion Methods 0.000 description 9
• 210000001165 lymph node Anatomy 0.000 description 9
• 244000052769 pathogen Species 0.000 description 9
• 210000001539 phagocyte Anatomy 0.000 description 9
• 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 8
• 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 8
• 102100032937 CD40 ligand Human genes 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 230000008901 benefit Effects 0.000 description 8
• 229960002685 biotin Drugs 0.000 description 8
• 239000011616 biotin Substances 0.000 description 8
• 150000001720 carbohydrates Chemical group 0.000 description 8
• 230000006378 damage Effects 0.000 description 8
• 238000005516 engineering process Methods 0.000 description 8
• 210000004408 hybridoma Anatomy 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 229940079322 interferon Drugs 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 8
• 239000003053 toxin Substances 0.000 description 8
• 231100000765 toxin Toxicity 0.000 description 8
• 108700012359 toxins Proteins 0.000 description 8
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 7
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 7
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 7
• 102000003810 Interleukin-18 Human genes 0.000 description 7
• 108090000171 Interleukin-18 Proteins 0.000 description 7
• 241001465754 Metazoa Species 0.000 description 7
• 102000006382 Ribonucleases Human genes 0.000 description 7
• 108010083644 Ribonucleases Proteins 0.000 description 7
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
• 102000008228 Toll-like receptor 2 Human genes 0.000 description 7
• 108010060888 Toll-like receptor 2 Proteins 0.000 description 7
• 235000020958 biotin Nutrition 0.000 description 7
• 230000000903 blocking effect Effects 0.000 description 7
• 150000001875 compounds Chemical class 0.000 description 7
• 239000000975 dye Substances 0.000 description 7
• 239000000839 emulsion Substances 0.000 description 7
• 230000006872 improvement Effects 0.000 description 7
• 230000001939 inductive effect Effects 0.000 description 7
• 230000003902 lesion Effects 0.000 description 7
• 239000003446 ligand Substances 0.000 description 7
• 244000045947 parasite Species 0.000 description 7
• 210000002966 serum Anatomy 0.000 description 7
• 238000013518 transcription Methods 0.000 description 7
• 230000035897 transcription Effects 0.000 description 7
• 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 6
• 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 6
• 102100024217 CAMPATH-1 antigen Human genes 0.000 description 6
• 108010065524 CD52 Antigen Proteins 0.000 description 6
• 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 6
• 101710190842 Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 6
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 6
• 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 6
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 6
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 6
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
• 102000014429 Insulin-like growth factor Human genes 0.000 description 6
• 102100025390 Integrin beta-2 Human genes 0.000 description 6
• 108010074328 Interferon-gamma Proteins 0.000 description 6
• 108010065805 Interleukin-12 Proteins 0.000 description 6
• 102000013462 Interleukin-12 Human genes 0.000 description 6
• 102000015696 Interleukins Human genes 0.000 description 6
• 108010063738 Interleukins Proteins 0.000 description 6
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 6
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 206010057249 Phagocytosis Diseases 0.000 description 6
• 230000003213 activating effect Effects 0.000 description 6
• 206010003246 arthritis Diseases 0.000 description 6
• 239000013522 chelant Substances 0.000 description 6
• 239000003246 corticosteroid Substances 0.000 description 6
• 238000005859 coupling reaction Methods 0.000 description 6
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
• 235000018417 cysteine Nutrition 0.000 description 6
• 231100000433 cytotoxic Toxicity 0.000 description 6
• 230000001472 cytotoxic effect Effects 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 208000026278 immune system disease Diseases 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 230000015788 innate immune response Effects 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 150000002500 ions Chemical class 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 108020004999 messenger RNA Proteins 0.000 description 6
• 230000005298 paramagnetic effect Effects 0.000 description 6
• 230000008782 phagocytosis Effects 0.000 description 6
• 125000003396 thiol group Chemical group [H]S* 0.000 description 6
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 5
• 108010053085 Complement Factor H Proteins 0.000 description 5
• 108020004635 Complementary DNA Proteins 0.000 description 5
• 241000233866 Fungi Species 0.000 description 5
• 229910052688 Gadolinium Inorganic materials 0.000 description 5
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 5
• 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 5
• 108060003951 Immunoglobulin Proteins 0.000 description 5
• 102000003814 Interleukin-10 Human genes 0.000 description 5
• 108090000174 Interleukin-10 Proteins 0.000 description 5
• 102000013691 Interleukin-17 Human genes 0.000 description 5
• 108050003558 Interleukin-17 Proteins 0.000 description 5
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
• 206010025323 Lymphomas Diseases 0.000 description 5
• 108091054438 MHC class II family Proteins 0.000 description 5
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 5
• 239000004365 Protease Substances 0.000 description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
• 230000003044 adaptive effect Effects 0.000 description 5
• 230000003110 anti-inflammatory effect Effects 0.000 description 5
• 230000003115 biocidal effect Effects 0.000 description 5
• 230000035602 clotting Effects 0.000 description 5
• 230000008878 coupling Effects 0.000 description 5
• 238000010168 coupling process Methods 0.000 description 5
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
• 229960004679 doxorubicin Drugs 0.000 description 5
• 239000013604 expression vector Substances 0.000 description 5
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 5
• 102000018358 immunoglobulin Human genes 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 230000002458 infectious effect Effects 0.000 description 5
• 208000032839 leukemia Diseases 0.000 description 5
• 125000005647 linker group Chemical group 0.000 description 5
• 239000002502 liposome Substances 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 238000002595 magnetic resonance imaging Methods 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 150000002739 metals Chemical class 0.000 description 5
• 229960000485 methotrexate Drugs 0.000 description 5
• 230000003472 neutralizing effect Effects 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 239000002245 particle Substances 0.000 description 5
• 229960003330 pentetic acid Drugs 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 229920001184 polypeptide Polymers 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• 238000011830 transgenic mouse model Methods 0.000 description 5
• 239000013598 vector Substances 0.000 description 5
• 230000003442 weekly effect Effects 0.000 description 5
• KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 4
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
• 108090001008 Avidin Proteins 0.000 description 4
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
• 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 4
• 102000011022 Chorionic Gonadotropin Human genes 0.000 description 4
• 108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
• 102000003951 Erythropoietin Human genes 0.000 description 4
• 108090000394 Erythropoietin Proteins 0.000 description 4
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
• 102100038651 Four and a half LIM domains protein 1 Human genes 0.000 description 4
• 101710127220 Four and a half LIM domains protein 1 Proteins 0.000 description 4
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 4
• 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 4
• 241000725303 Human immunodeficiency virus Species 0.000 description 4
• 102000008070 Interferon-gamma Human genes 0.000 description 4
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 4
• 102000003812 Interleukin-15 Human genes 0.000 description 4
• 108090000172 Interleukin-15 Proteins 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• 102000000588 Interleukin-2 Human genes 0.000 description 4
• 108090000978 Interleukin-4 Proteins 0.000 description 4
• 102000004388 Interleukin-4 Human genes 0.000 description 4
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 4
• 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 4
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 4
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 4
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 4
• 108091054437 MHC class I family Proteins 0.000 description 4
• 102000043131 MHC class II family Human genes 0.000 description 4
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
• 102100023123 Mucin-16 Human genes 0.000 description 4
• 241000699660 Mus musculus Species 0.000 description 4
• 241000204031 Mycoplasma Species 0.000 description 4
• 102100035194 Placenta growth factor Human genes 0.000 description 4
• 206010035664 Pneumonia Diseases 0.000 description 4
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
• 102100038358 Prostate-specific antigen Human genes 0.000 description 4
• 241000219061 Rheum Species 0.000 description 4
• 241000283984 Rodentia Species 0.000 description 4
• 108010090804 Streptavidin Proteins 0.000 description 4
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 4
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 238000010804 cDNA synthesis Methods 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 239000005482 chemotactic factor Substances 0.000 description 4
• 210000000038 chest Anatomy 0.000 description 4
• 238000010367 cloning Methods 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 229960001334 corticosteroids Drugs 0.000 description 4
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
• 239000000032 diagnostic agent Substances 0.000 description 4
• 229940039227 diagnostic agent Drugs 0.000 description 4
• AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 4
• 229940105423 erythropoietin Drugs 0.000 description 4
• 229960002949 fluorouracil Drugs 0.000 description 4
• 239000003862 glucocorticoid Substances 0.000 description 4
• 230000003394 haemopoietic effect Effects 0.000 description 4
• 210000003630 histaminocyte Anatomy 0.000 description 4
• 229940084986 human chorionic gonadotropin Drugs 0.000 description 4
• 210000002865 immune cell Anatomy 0.000 description 4
• 230000028709 inflammatory response Effects 0.000 description 4
• 229940028885 interleukin-4 Drugs 0.000 description 4
• 229910052742 iron Inorganic materials 0.000 description 4
• 230000002147 killing effect Effects 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 239000011572 manganese Substances 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 230000000813 microbial effect Effects 0.000 description 4
• 238000002823 phage display Methods 0.000 description 4
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
• 229960004618 prednisone Drugs 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 238000002604 ultrasonography Methods 0.000 description 4
• FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
• LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 3
• 108010066676 Abrin Proteins 0.000 description 3
• 108010089414 Anaphylatoxins Proteins 0.000 description 3
• 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 3
• 108050001427 Avidin/streptavidin Proteins 0.000 description 3
• 102100032412 Basigin Human genes 0.000 description 3
• 229920002498 Beta-glucan Polymers 0.000 description 3
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
• 108010029697 CD40 Ligand Proteins 0.000 description 3
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 3
• 108010055166 Chemokine CCL5 Proteins 0.000 description 3
• 102100035432 Complement factor H Human genes 0.000 description 3
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
• 108010053187 Diphtheria Toxin Proteins 0.000 description 3
• 102000016607 Diphtheria Toxin Human genes 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 108010009900 Endothelial Protein C Receptor Proteins 0.000 description 3
• 102000009839 Endothelial Protein C Receptor Human genes 0.000 description 3
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 3
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
• 102000003886 Glycoproteins Human genes 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000798441 Homo sapiens Basigin Proteins 0.000 description 3
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
• 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 3
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 102100025304 Integrin beta-1 Human genes 0.000 description 3
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 3
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 3
• 102000004559 Interleukin-13 Receptors Human genes 0.000 description 3
• 108010017511 Interleukin-13 Receptors Proteins 0.000 description 3
• 102000004556 Interleukin-15 Receptors Human genes 0.000 description 3
• 108010017535 Interleukin-15 Receptors Proteins 0.000 description 3
• 102000004557 Interleukin-18 Receptors Human genes 0.000 description 3
• 108010017537 Interleukin-18 Receptors Proteins 0.000 description 3
• 102000010787 Interleukin-4 Receptors Human genes 0.000 description 3
• 108010038486 Interleukin-4 Receptors Proteins 0.000 description 3
• 102100039897 Interleukin-5 Human genes 0.000 description 3
• 108010002616 Interleukin-5 Proteins 0.000 description 3
• 108090001030 Lipoproteins Proteins 0.000 description 3
• 102000004895 Lipoproteins Human genes 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
• 102000043129 MHC class I family Human genes 0.000 description 3
• 206010027457 Metastases to liver Diseases 0.000 description 3
• 208000010718 Multiple Organ Failure Diseases 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 108010057466 NF-kappa B Proteins 0.000 description 3
• 102000003945 NF-kappa B Human genes 0.000 description 3
• 229930012538 Paclitaxel Natural products 0.000 description 3
• 102000035195 Peptidases Human genes 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• 206010036030 Polyarthritis Diseases 0.000 description 3
• 229940079156 Proteasome inhibitor Drugs 0.000 description 3
• 108010094028 Prothrombin Proteins 0.000 description 3
• 102100027378 Prothrombin Human genes 0.000 description 3
• 241000589516 Pseudomonas Species 0.000 description 3
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 3
• 108091030071 RNAI Proteins 0.000 description 3
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
• 108010039491 Ricin Proteins 0.000 description 3
• 108020004682 Single-Stranded DNA Proteins 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 230000024932 T cell mediated immunity Effects 0.000 description 3
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 230000004721 adaptive immunity Effects 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 125000000539 amino acid group Chemical group 0.000 description 3
• 230000000340 anti-metabolite Effects 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 229940100197 antimetabolite Drugs 0.000 description 3
• 239000002256 antimetabolite Substances 0.000 description 3
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
• 230000001588 bifunctional effect Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 210000002798 bone marrow cell Anatomy 0.000 description 3
• 150000001639 boron compounds Chemical class 0.000 description 3
• 239000006227 byproduct Substances 0.000 description 3
• 229940127093 camptothecin Drugs 0.000 description 3
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 239000013599 cloning vector Substances 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 102000006834 complement receptors Human genes 0.000 description 3
• 108010047295 complement receptors Proteins 0.000 description 3
• 230000004154 complement system Effects 0.000 description 3
• 230000001268 conjugating effect Effects 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 102000003675 cytokine receptors Human genes 0.000 description 3
• 108010057085 cytokine receptors Proteins 0.000 description 3
• 230000009089 cytolysis Effects 0.000 description 3
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 3
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
• 210000003162 effector t lymphocyte Anatomy 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 235000019197 fats Nutrition 0.000 description 3
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
• 239000007850 fluorescent dye Substances 0.000 description 3
• 108020005243 folate receptor Proteins 0.000 description 3
• 102000006815 folate receptor Human genes 0.000 description 3
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
• 229960005277 gemcitabine Drugs 0.000 description 3
• 230000009368 gene silencing by RNA Effects 0.000 description 3
• 239000010931 gold Substances 0.000 description 3
• 210000002443 helper t lymphocyte Anatomy 0.000 description 3
• 238000003384 imaging method Methods 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 230000001506 immunosuppresive effect Effects 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 229940047124 interferons Drugs 0.000 description 3
• 229940100602 interleukin-5 Drugs 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 239000002960 lipid emulsion Substances 0.000 description 3
• 210000004324 lymphatic system Anatomy 0.000 description 3
• WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 3
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
• 230000001338 necrotic effect Effects 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 229960001592 paclitaxel Drugs 0.000 description 3
• 230000000242 pagocytic effect Effects 0.000 description 3
• 230000010412 perfusion Effects 0.000 description 3
• 108700028325 pokeweed antiviral Proteins 0.000 description 3
• 208000030428 polyarticular arthritis Diseases 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 238000003752 polymerase chain reaction Methods 0.000 description 3
• 239000003207 proteasome inhibitor Substances 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 102000037983 regulatory factors Human genes 0.000 description 3
• 108091008025 regulatory factors Proteins 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 229940037128 systemic glucocorticoids Drugs 0.000 description 3
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
• 230000036325 urinary excretion Effects 0.000 description 3
• 230000009385 viral infection Effects 0.000 description 3
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 2
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
• VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 2
• JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 2
• 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
• 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 108010022752 Acetylcholinesterase Proteins 0.000 description 2
• 102000012440 Acetylcholinesterase Human genes 0.000 description 2
• 102000013563 Acid Phosphatase Human genes 0.000 description 2
• 108010051457 Acid Phosphatase Proteins 0.000 description 2
• 206010048998 Acute phase reaction Diseases 0.000 description 2
• 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
• 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
• 101710092462 Alpha-hemolysin Proteins 0.000 description 2
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 108010024976 Asparaginase Proteins 0.000 description 2
• 102000015790 Asparaginase Human genes 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 102100026189 Beta-galactosidase Human genes 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 102100036842 C-C motif chemokine 19 Human genes 0.000 description 2
• 102100036846 C-C motif chemokine 21 Human genes 0.000 description 2
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
• 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 2
• 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 2
• 108700012439 CA9 Proteins 0.000 description 2
• 102100027207 CD27 antigen Human genes 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 102100035882 Catalase Human genes 0.000 description 2
• 108010053835 Catalase Proteins 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 102000016550 Complement Factor H Human genes 0.000 description 2
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
• 208000000059 Dyspnea Diseases 0.000 description 2
• 206010013975 Dyspnoeas Diseases 0.000 description 2
• 229910052692 Dysprosium Inorganic materials 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 108010079505 Endostatins Proteins 0.000 description 2
• 102100023688 Eotaxin Human genes 0.000 description 2
• 101710139422 Eotaxin Proteins 0.000 description 2
• 241001480035 Epidermophyton Species 0.000 description 2
• 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 208000010201 Exanthema Diseases 0.000 description 2
• 108010054265 Factor VIIa Proteins 0.000 description 2
• GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
• 208000032612 Glial tumor Diseases 0.000 description 2
• 206010018338 Glioma Diseases 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
• 102100022624 Glucoamylase Human genes 0.000 description 2
• 108010015776 Glucose oxidase Proteins 0.000 description 2
• 239000004366 Glucose oxidase Substances 0.000 description 2
• 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
• 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 2
• 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 2
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 102000006354 HLA-DR Antigens Human genes 0.000 description 2
• 108010058597 HLA-DR Antigens Proteins 0.000 description 2
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
• 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 2
• 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 2
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
• 101100061856 Homo sapiens CXCL2 gene Proteins 0.000 description 2
• 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 2
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
• 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
• 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 2
• 101000972284 Homo sapiens Mucin-3A Proteins 0.000 description 2
• 101000972286 Homo sapiens Mucin-4 Proteins 0.000 description 2
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
• 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 2
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
• 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
• 208000029462 Immunodeficiency disease Diseases 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 102100022338 Integrin alpha-M Human genes 0.000 description 2
• 102100022297 Integrin alpha-X Human genes 0.000 description 2
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
• 102100037850 Interferon gamma Human genes 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102000003996 Interferon-beta Human genes 0.000 description 2
• 108090000467 Interferon-beta Proteins 0.000 description 2
• 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
• 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
• 102000004554 Interleukin-17 Receptors Human genes 0.000 description 2
• 108010017525 Interleukin-17 Receptors Proteins 0.000 description 2
• 102100030703 Interleukin-22 Human genes 0.000 description 2
• 108010002386 Interleukin-3 Proteins 0.000 description 2
• 102000000646 Interleukin-3 Human genes 0.000 description 2
• 102000004195 Isomerases Human genes 0.000 description 2
• 108090000769 Isomerases Proteins 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• 238000012307 MRI technique Methods 0.000 description 2
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
• 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 2
• 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 2
• 102000013460 Malate Dehydrogenase Human genes 0.000 description 2
• 108010026217 Malate Dehydrogenase Proteins 0.000 description 2
• WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 108010059724 Micrococcal Nuclease Proteins 0.000 description 2
• 102100034263 Mucin-2 Human genes 0.000 description 2
• 102100022497 Mucin-3A Human genes 0.000 description 2
• 102100022693 Mucin-4 Human genes 0.000 description 2
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
• 241000243985 Onchocerca volvulus Species 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 241000282520 Papio Species 0.000 description 2
• 208000030852 Parasitic disease Diseases 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
• 208000035415 Reinfection Diseases 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 108010084592 Saporins Proteins 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 206010058556 Serositis Diseases 0.000 description 2
• 102100035721 Syndecan-1 Human genes 0.000 description 2
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
• 208000000389 T-cell leukemia Diseases 0.000 description 2
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
• 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 2
• 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 2
• 208000001871 Tachycardia Diseases 0.000 description 2
• 208000001106 Takayasu Arteritis Diseases 0.000 description 2
• 229940123237 Taxane Drugs 0.000 description 2
• 102100038126 Tenascin Human genes 0.000 description 2
• 108010008125 Tenascin Proteins 0.000 description 2
• 229910052771 Terbium Inorganic materials 0.000 description 2
• 102100026966 Thrombomodulin Human genes 0.000 description 2
• 108010079274 Thrombomodulin Proteins 0.000 description 2
• 102000036693 Thrombopoietin Human genes 0.000 description 2
• 108010041111 Thrombopoietin Proteins 0.000 description 2
• 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 description 2
• 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 2
• 108700015934 Triose-phosphate isomerases Proteins 0.000 description 2
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
• 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 2
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
• 108010046334 Urease Proteins 0.000 description 2
• 108091008605 VEGF receptors Proteins 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 229940122803 Vinca alkaloid Drugs 0.000 description 2
• 229930003779 Vitamin B12 Natural products 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 229940022698 acetylcholinesterase Drugs 0.000 description 2
• 230000004658 acute-phase response Effects 0.000 description 2
• 230000008649 adaptation response Effects 0.000 description 2
• 230000033289 adaptive immune response Effects 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 150000008052 alkyl sulfonates Chemical class 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
• 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
• 229960004238 anakinra Drugs 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 229940045799 anthracyclines and related substance Drugs 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 238000009175 antibody therapy Methods 0.000 description 2
• 239000003080 antimitotic agent Substances 0.000 description 2
• 239000000074 antisense oligonucleotide Substances 0.000 description 2
• 238000012230 antisense oligonucleotides Methods 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• 206010003230 arteritis Diseases 0.000 description 2
• 229960003272 asparaginase Drugs 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 229910052788 barium Inorganic materials 0.000 description 2
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 108010027090 biotin-streptavidin complex Proteins 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 231100001018 bone marrow damage Toxicity 0.000 description 2
• 235000013877 carbamide Nutrition 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 239000011651 chromium Substances 0.000 description 2
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 229910052802 copper Inorganic materials 0.000 description 2
• 229940111134 coxibs Drugs 0.000 description 2
• 229940109239 creatinine Drugs 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
• 230000016396 cytokine production Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007123 defense Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• 238000002059 diagnostic imaging Methods 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 2
• 239000002961 echo contrast media Substances 0.000 description 2
• 210000003989 endothelium vascular Anatomy 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 231100000655 enterotoxin Toxicity 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 201000005884 exanthem Diseases 0.000 description 2
• 229940012414 factor viia Drugs 0.000 description 2
• 229960000390 fludarabine Drugs 0.000 description 2
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
• 238000002594 fluoroscopy Methods 0.000 description 2
• 150000002224 folic acids Chemical class 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 229910052733 gallium Inorganic materials 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 229940116332 glucose oxidase Drugs 0.000 description 2
• 235000019420 glucose oxidase Nutrition 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
• 210000000777 hematopoietic system Anatomy 0.000 description 2
• 229960001340 histamine Drugs 0.000 description 2
• 230000005745 host immune response Effects 0.000 description 2
• 230000028996 humoral immune response Effects 0.000 description 2
• 230000004727 humoral immunity Effects 0.000 description 2
• 230000007954 hypoxia Effects 0.000 description 2
• 239000012216 imaging agent Substances 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229960003130 interferon gamma Drugs 0.000 description 2
• 108010074108 interleukin-21 Proteins 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 108010028930 invariant chain Proteins 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 230000003907 kidney function Effects 0.000 description 2
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 210000003712 lysosome Anatomy 0.000 description 2
• 230000001868 lysosomic effect Effects 0.000 description 2
• 230000002101 lytic effect Effects 0.000 description 2
• 201000004792 malaria Diseases 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 229940118019 malondialdehyde Drugs 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 238000012737 microarray-based gene expression Methods 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 2
• 238000006386 neutralization reaction Methods 0.000 description 2
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 2
• 230000014207 opsonization Effects 0.000 description 2
• 230000008816 organ damage Effects 0.000 description 2
• 230000004768 organ dysfunction Effects 0.000 description 2
• 210000004789 organ system Anatomy 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 229940055729 papain Drugs 0.000 description 2
• 235000019834 papain Nutrition 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 238000002428 photodynamic therapy Methods 0.000 description 2
• 238000001126 phototherapy Methods 0.000 description 2
• 239000000049 pigment Substances 0.000 description 2
• 229910052697 platinum Inorganic materials 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229940068968 polysorbate 80 Drugs 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 150000004032 porphyrins Chemical class 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000007112 pro inflammatory response Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 239000003805 procoagulant Substances 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• 230000000644 propagated effect Effects 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 229940039716 prothrombin Drugs 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 150000003212 purines Chemical class 0.000 description 2
• 150000003230 pyrimidines Chemical class 0.000 description 2
• 206010037844 rash Diseases 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 229960004641 rituximab Drugs 0.000 description 2
• CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
• 229940076279 serotonin Drugs 0.000 description 2
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 230000006794 tachycardia Effects 0.000 description 2
• 101150047061 tag-72 gene Proteins 0.000 description 2
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
• GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000014616 translation Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• AYNNSCRYTDRFCP-UHFFFAOYSA-N triazene Chemical compound NN=N AYNNSCRYTDRFCP-UHFFFAOYSA-N 0.000 description 2
• 230000005951 type IV hypersensitivity Effects 0.000 description 2
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
• 150000003672 ureas Chemical class 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• 229910052720 vanadium Inorganic materials 0.000 description 2
• 210000003556 vascular endothelial cell Anatomy 0.000 description 2
• 239000011715 vitamin B12 Substances 0.000 description 2
• 235000019163 vitamin B12 Nutrition 0.000 description 2
• BNIFSVVAHBLNTN-XKKUQSFHSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexan Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 BNIFSVVAHBLNTN-XKKUQSFHSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• DFDJVFYYDGMDTB-BIYVAJLZSA-N 1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[[(3s,4r,5s)-3,4,5,6-tetrahydroxy-2-oxohexanoyl]amino]benzene-1,3-dicarboxamide Chemical compound OCC(O)CNC(=O)C1=C(I)C(NC(=O)C(=O)[C@@H](O)[C@H](O)[C@@H](O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I DFDJVFYYDGMDTB-BIYVAJLZSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• QPHJQCAPTXSDDP-UHFFFAOYSA-N 2-phenyl-2,7-diazaspiro[4.4]nonane Chemical compound C1NCCC11CN(C=2C=CC=CC=2)CC1 QPHJQCAPTXSDDP-UHFFFAOYSA-N 0.000 description 1
• LLLMGEDYKIIGPY-UHFFFAOYSA-N 3-[3-[acetyl(ethyl)amino]-2,4,6-triiodophenyl]propanoic acid Chemical compound CCN(C(C)=O)C1=C(I)C=C(I)C(CCC(O)=O)=C1I LLLMGEDYKIIGPY-UHFFFAOYSA-N 0.000 description 1
• IRYYCWRQWAKJMU-WZTVWXICSA-N 3-[acetyl(ethyl)amino]-5-[3-[3-[3-[acetyl(ethyl)amino]-5-carboxy-2,4,6-triiodoanilino]-3-oxopropyl]sulfonylpropanoylamino]-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)C1=C(I)C(N(C(C)=O)CC)=C(I)C(NC(=O)CCS(=O)(=O)CCC(=O)NC=2C(=C(C(O)=O)C(I)=C(N(CC)C(C)=O)C=2I)I)=C1I IRYYCWRQWAKJMU-WZTVWXICSA-N 0.000 description 1
• OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
• OQHLOKBHRXMXLD-UHFFFAOYSA-N 5-[3-[3-[3,5-bis[2,3-dihydroxypropyl(methyl)carbamoyl]-2,4,6-triiodoanilino]-3-oxopropyl]sulfanylpropanoylamino]-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1-n,3-n-dimethylbenzene-1,3-dicarboxamide Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(C(=O)N(CC(O)CO)C)=C(I)C(NC(=O)CCSCCC(=O)NC=2C(=C(C(=O)N(C)CC(O)CO)C(I)=C(C(=O)N(C)CC(O)CO)C=2I)I)=C1I OQHLOKBHRXMXLD-UHFFFAOYSA-N 0.000 description 1
• YEEGWNXDUZONAA-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-gallabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Ga+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YEEGWNXDUZONAA-UHFFFAOYSA-K 0.000 description 1
• GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• 241000203024 Acholeplasma Species 0.000 description 1
• 208000010444 Acidosis Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 102100036664 Adenosine deaminase Human genes 0.000 description 1
• 108091093088 Amplicon Proteins 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 208000008286 Aortic Arch Syndromes Diseases 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 101710192393 Attachment protein G3P Proteins 0.000 description 1
• 241000223838 Babesia bovis Species 0.000 description 1
• 241000193738 Bacillus anthracis Species 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 206010004659 Biliary cirrhosis Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 241000120506 Bluetongue virus Species 0.000 description 1
• 206010051779 Bone marrow toxicity Diseases 0.000 description 1
• 241000589969 Borreliella burgdorferi Species 0.000 description 1
• 244000056139 Brassica cretica Species 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 241000589567 Brucella abortus Species 0.000 description 1
• 108010074051 C-Reactive Protein Proteins 0.000 description 1
• 102100032752 C-reactive protein Human genes 0.000 description 1
• 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
• 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
• 108010055167 CD59 Antigens Proteins 0.000 description 1
• 102000001324 CD59 Antigens Human genes 0.000 description 1
• 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 101710169873 Capsid protein G8P Proteins 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 241000207199 Citrus Species 0.000 description 1
• 102100022641 Coagulation factor IX Human genes 0.000 description 1
• 102100023804 Coagulation factor VII Human genes 0.000 description 1
• 241000223203 Coccidioides Species 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• 108700040183 Complement C1 Inhibitor Proteins 0.000 description 1
• 102000055157 Complement C1 Inhibitor Human genes 0.000 description 1
• 108010078546 Complement C5a Proteins 0.000 description 1
• 102000000989 Complement System Proteins Human genes 0.000 description 1
• 108010069112 Complement System Proteins Proteins 0.000 description 1
• 108090000056 Complement factor B Proteins 0.000 description 1
• 102000003712 Complement factor B Human genes 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 201000003808 Cystic echinococcosis Diseases 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• 241000725619 Dengue virus Species 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 241000244170 Echinococcus granulosus Species 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
• 206010048554 Endothelial dysfunction Diseases 0.000 description 1
• 208000037487 Endotoxemia Diseases 0.000 description 1
• 101710146739 Enterotoxin Proteins 0.000 description 1
• 241000991587 Enterovirus C Species 0.000 description 1
• 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
• 229910052691 Erbium Inorganic materials 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 206010015226 Erythema nodosum Diseases 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• 229910052693 Europium Inorganic materials 0.000 description 1
• 208000009386 Experimental Arthritis Diseases 0.000 description 1
• 108010076282 Factor IX Proteins 0.000 description 1
• 108010023321 Factor VII Proteins 0.000 description 1
• 108010014173 Factor X Proteins 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
• 241000714165 Feline leukemia virus Species 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 108090000270 Ficain Proteins 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• 206010016717 Fistula Diseases 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 206010019851 Hepatotoxicity Diseases 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 241000228404 Histoplasma capsulatum Species 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 229910052689 Holmium Inorganic materials 0.000 description 1
• 101000900688 Homo sapiens Grancalcin Proteins 0.000 description 1
• 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
• 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 1
• 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
• 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
• 206010021263 IgA nephropathy Diseases 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
• SMQYOVYWPWASGU-UHFFFAOYSA-N Iocarmic acid Chemical compound OC(=O)C1=C(I)C(C(=O)NC)=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(=O)NC)C(I)=C(C(O)=O)C=2I)I)=C1I SMQYOVYWPWASGU-UHFFFAOYSA-N 0.000 description 1
• WWVAPFRKZMUPHZ-UHFFFAOYSA-N Iodoxamic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCOCCOCCOCCOCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I WWVAPFRKZMUPHZ-UHFFFAOYSA-N 0.000 description 1
• OIRFJRBSRORBCM-UHFFFAOYSA-N Iopanoic acid Chemical compound CCC(C(O)=O)CC1=C(I)C=C(I)C(N)=C1I OIRFJRBSRORBCM-UHFFFAOYSA-N 0.000 description 1
• UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 241000222736 Leishmania tropica Species 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
• 101150058224 MIF gene Proteins 0.000 description 1
• 239000002616 MRI contrast agent Substances 0.000 description 1
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
• 101710125418 Major capsid protein Proteins 0.000 description 1
• 101710156564 Major tail protein Gp23 Proteins 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
• 241000712079 Measles morbillivirus Species 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 101710146216 Membrane cofactor protein Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 206010027458 Metastases to lung Diseases 0.000 description 1
• BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
• 231100000757 Microbial toxin Toxicity 0.000 description 1
• 241000243190 Microsporidia Species 0.000 description 1
• 241001480037 Microsporum Species 0.000 description 1
• 241001430197 Mollicutes Species 0.000 description 1
• 208000034486 Multi-organ failure Diseases 0.000 description 1
• 241000711386 Mumps virus Species 0.000 description 1
• 241000711408 Murine respirovirus Species 0.000 description 1
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 241000186362 Mycobacterium leprae Species 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 241000204028 Mycoplasma arginini Species 0.000 description 1
• 241000202938 Mycoplasma hyorhinis Species 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
• 241000588650 Neisseria meningitidis Species 0.000 description 1
• 229910052779 Neodymium Inorganic materials 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
• 108700022034 Opsonin Proteins Proteins 0.000 description 1
• 241000658540 Ora Species 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 241000283898 Ovis Species 0.000 description 1
• 206010033557 Palpitations Diseases 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 108010053210 Phycocyanin Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 241000404883 Pisa Species 0.000 description 1
• 241000223960 Plasmodium falciparum Species 0.000 description 1
• 241000223810 Plasmodium vivax Species 0.000 description 1
• 208000005374 Poisoning Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 206010065159 Polychondritis Diseases 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 102100038567 Properdin Human genes 0.000 description 1
• 108010005642 Properdin Proteins 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 241000711798 Rabies lyssavirus Species 0.000 description 1
• 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038019 Rectal adenocarcinoma Diseases 0.000 description 1
• 241000702263 Reovirus sp. Species 0.000 description 1
• 241000725643 Respiratory syncytial virus Species 0.000 description 1
• 241000606701 Rickettsia Species 0.000 description 1
• 241000710799 Rubella virus Species 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 239000002262 Schiff base Substances 0.000 description 1
• 150000004753 Schiff bases Chemical class 0.000 description 1
• 241000242678 Schistosoma Species 0.000 description 1
• 241000242680 Schistosoma mansoni Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 208000019802 Sexually transmitted disease Diseases 0.000 description 1
• 241000710960 Sindbis virus Species 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 241001479493 Sousa Species 0.000 description 1
• 241000589970 Spirochaetales Species 0.000 description 1
• 241000191940 Staphylococcus Species 0.000 description 1
• 241000193985 Streptococcus agalactiae Species 0.000 description 1
• 241000193996 Streptococcus pyogenes Species 0.000 description 1
• 108700005078 Synthetic Genes Proteins 0.000 description 1
• 208000004732 Systemic Vasculitis Diseases 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 241000244155 Taenia Species 0.000 description 1
• 241000244159 Taenia saginata Species 0.000 description 1
• 108010055044 Tetanus Toxin Proteins 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 241000223779 Theileria parva Species 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 208000002474 Tinea Diseases 0.000 description 1
• 102100030859 Tissue factor Human genes 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 241000223997 Toxoplasma gondii Species 0.000 description 1
• 241000589884 Treponema pallidum Species 0.000 description 1
• 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
• 241000243777 Trichinella spiralis Species 0.000 description 1
• 241000223238 Trichophyton Species 0.000 description 1
• 241000893966 Trichophyton verrucosum Species 0.000 description 1
• BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
• PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 241000223104 Trypanosoma Species 0.000 description 1
• 241000223105 Trypanosoma brucei Species 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 241000223097 Trypanosoma rangeli Species 0.000 description 1
• 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 206010047111 Vasculitic rash Diseases 0.000 description 1
• 241000711975 Vesicular stomatitis virus Species 0.000 description 1
• 108700005077 Viral Genes Proteins 0.000 description 1
• 238000012452 Xenomouse strains Methods 0.000 description 1
• 229910052769 Ytterbium Inorganic materials 0.000 description 1
• 230000007950 acidosis Effects 0.000 description 1
• 208000026545 acidosis disease Diseases 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• FFINMCNLQNTKLU-UHFFFAOYSA-N adipiodone Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I FFINMCNLQNTKLU-UHFFFAOYSA-N 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 210000004404 adrenal cortex Anatomy 0.000 description 1
• 230000001780 adrenocortical effect Effects 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 108010004469 allophycocyanin Proteins 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
• 150000001412 amines Chemical group 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 210000004381 amniotic fluid Anatomy 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 210000004198 anterior pituitary gland Anatomy 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 230000002927 anti-mitotic effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000002137 anti-vascular effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940124350 antibacterial drug Drugs 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 230000010100 anticoagulation Effects 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 230000007503 antigenic stimulation Effects 0.000 description 1
• 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 210000002376 aorta thoracic Anatomy 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 230000036528 appetite Effects 0.000 description 1
• 235000019789 appetite Nutrition 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 239000005667 attractant Substances 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 150000001553 barium compounds Chemical class 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 238000005842 biochemical reaction Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 238000009640 blood culture Methods 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 231100000366 bone marrow toxicity Toxicity 0.000 description 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
• 230000003925 brain function Effects 0.000 description 1
• 229940056450 brucella abortus Drugs 0.000 description 1
• 229960005520 bryostatin Drugs 0.000 description 1
• MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
• MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
• 229930195731 calicheamicin Natural products 0.000 description 1
• 230000005880 cancer cell killing Effects 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000000837 carbohydrate group Chemical group 0.000 description 1
• 230000002612 cardiopulmonary effect Effects 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 208000026915 cervical aortic arch Diseases 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 230000031902 chemoattractant activity Effects 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 238000011976 chest X-ray Methods 0.000 description 1
• 210000001612 chondrocyte Anatomy 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
• 235000020971 citrus fruits Nutrition 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 229910017052 cobalt Inorganic materials 0.000 description 1
• 239000010941 cobalt Substances 0.000 description 1
• GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
• XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
• 239000007957 coemulsifier Substances 0.000 description 1
• 238000009096 combination chemotherapy Methods 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 150000003983 crown ethers Chemical class 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000004665 defense response Effects 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 229940029030 dendritic cell vaccine Drugs 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 229960005423 diatrizoate Drugs 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 238000001839 endoscopy Methods 0.000 description 1
• 230000008694 endothelial dysfunction Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 108091007231 endothelial receptors Proteins 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 239000000147 enterotoxin Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
• 229950009760 epratuzumab Drugs 0.000 description 1
• UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• 229940011957 ethiodized oil Drugs 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000011347 external beam therapy Methods 0.000 description 1
• 229960004222 factor ix Drugs 0.000 description 1
• 229940012413 factor vii Drugs 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 230000020764 fibrinolysis Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 235000019836 ficin Nutrition 0.000 description 1
• POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
• 230000003890 fistula Effects 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
• 238000001215 fluorescent labelling Methods 0.000 description 1
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 150000002259 gallium compounds Chemical class 0.000 description 1
• 230000005251 gamma ray Effects 0.000 description 1
• 108010074605 gamma-Globulins Proteins 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000005227 gel permeation chromatography Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• CBMIPXHVOVTTTL-UHFFFAOYSA-N gold(3+) Chemical compound [Au+3] CBMIPXHVOVTTTL-UHFFFAOYSA-N 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 244000000013 helminth Species 0.000 description 1
• 210000003566 hemangioblast Anatomy 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 230000002439 hemostatic effect Effects 0.000 description 1
• 231100000304 hepatotoxicity Toxicity 0.000 description 1
• 230000007686 hepatotoxicity Effects 0.000 description 1
• KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
• SCKNFLZJSOHWIV-UHFFFAOYSA-N holmium(3+) Chemical compound [Ho+3] SCKNFLZJSOHWIV-UHFFFAOYSA-N 0.000 description 1
• 230000007236 host immunity Effects 0.000 description 1
• 102000050520 human GCA Human genes 0.000 description 1
• 238000011577 humanized mouse model Methods 0.000 description 1
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• 150000002466 imines Chemical group 0.000 description 1
• 230000006450 immune cell response Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 239000012133 immunoprecipitate Substances 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940124589 immunosuppressive drug Drugs 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 208000033065 inborn errors of immunity Diseases 0.000 description 1
• 229940060367 inert ingredients Drugs 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940117681 interleukin-12 Drugs 0.000 description 1
• 230000017306 interleukin-6 production Effects 0.000 description 1
• 230000021995 interleukin-8 production Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 229960002517 iocarmic acid Drugs 0.000 description 1
• VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 description 1
• 229960004901 iodamide Drugs 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 150000002497 iodine compounds Chemical class 0.000 description 1
• 229940029355 iodipamide Drugs 0.000 description 1
• 229960002487 iodoxamic acid Drugs 0.000 description 1
• NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
• 229960001025 iohexol Drugs 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
• 229960004647 iopamidol Drugs 0.000 description 1
• 229960002979 iopanoic acid Drugs 0.000 description 1
• 229950008924 ioprocemic acid Drugs 0.000 description 1
• 229960000929 iotalamic acid Drugs 0.000 description 1
• 229950011097 iotasul Drugs 0.000 description 1
• 229960000506 iotroxic acid Drugs 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 229940054136 kineret Drugs 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• CZMAIROVPAYCMU-UHFFFAOYSA-N lanthanum(3+) Chemical compound [La+3] CZMAIROVPAYCMU-UHFFFAOYSA-N 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• 231100000225 lethality Toxicity 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 231100000516 lung damage Toxicity 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 108010057531 macrophage migration inhibitory factor receptor Proteins 0.000 description 1
• 230000005291 magnetic effect Effects 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
• 231100000855 membranous nephropathy Toxicity 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 1
• 229960000554 metrizamide Drugs 0.000 description 1
• 229960004712 metrizoic acid Drugs 0.000 description 1
• GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• 230000036473 myasthenia Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 229940014456 mycophenolate Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 210000004296 naive t lymphocyte Anatomy 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
• 230000003880 negative regulation of appetite Effects 0.000 description 1
• 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 231100000926 not very toxic Toxicity 0.000 description 1
• 230000001473 noxious effect Effects 0.000 description 1
• 238000012633 nuclear imaging Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 229940054441 o-phthalaldehyde Drugs 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 230000003571 opsonizing effect Effects 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 108010012038 peptide 78 Proteins 0.000 description 1
• 229940125863 peptide 78 Drugs 0.000 description 1
• 229950009215 phenylbutanoic acid Drugs 0.000 description 1
• 108010055837 phosphocarrier protein HPr Proteins 0.000 description 1
• 239000000906 photoactive agent Substances 0.000 description 1
• ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 229920000570 polyether Polymers 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 238000011248 postoperative chemotherapy Methods 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 238000007639 printing Methods 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 230000002947 procoagulating effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 239000012857 radioactive material Substances 0.000 description 1
• 238000011127 radiochemotherapy Methods 0.000 description 1
• 108010061338 ranpirnase Proteins 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 230000019254 respiratory burst Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 229910052702 rhenium Inorganic materials 0.000 description 1
• WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 231100000046 skin rash Toxicity 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 208000023516 stroke disease Diseases 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 230000000153 supplemental effect Effects 0.000 description 1
• 238000002636 symptomatic treatment Methods 0.000 description 1
• 229940118376 tetanus toxin Drugs 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229910052716 thallium Inorganic materials 0.000 description 1
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
• 150000003476 thallium compounds Chemical class 0.000 description 1
• GBECUEIQVRDUKB-UHFFFAOYSA-M thallium monochloride Chemical compound [Tl]Cl GBECUEIQVRDUKB-UHFFFAOYSA-M 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 208000013076 thyroid tumor Diseases 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000003151 transfection method Methods 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 229940096911 trichinella spiralis Drugs 0.000 description 1
• PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
• 229940117972 triolein Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 230000005909 tumor killing Effects 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 229940099039 velcade Drugs 0.000 description 1
• 230000008189 vertebrate development Effects 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 239000011800 void material Substances 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1